Program
Carboplatin
Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.
Drug pageCarboplatin: every studyMany companies study it; this page follows only the 89 they lead. All 1,229 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 300 open or running | phase 4since Nov 24, 2009 | Apr 30, 2002 | none ahead |
| Bristol-Myers Squibbits history only | 140 open or running | phase 4since May 28, 2014 | Sep 13, 2001 | none ahead |
| Sanofiits history only | 70 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sarah Cannon Research Instituteits history only | 31 open or running | phase 2since Nov 2, 2005 | Nov 2, 2005 | none ahead |
| Swedish Orphan Biovitrumits history only | 30 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| AGO Researchits history only | 20 open or running | phase 3since Apr 16, 2013 | Apr 16, 2013 | none ahead |
| CarTheraits history only | 21 open or running | phase 3since Jun 5, 2023 | Nov 13, 2018 | Jan 28, 2028phase 3 · NCT05902169 |
| Eisaiits history only | 20 open or running | phase 3since Dec 31, 2002 | Dec 31, 2002 | none ahead |
| InSightecits history only | 20 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Ionis Pharmaceuticalsits history only | 20 open or running | phase 3since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| Johnson & Johnsonits history only | 21 open or running | phase 3since Aug 31, 2020 | Jun 12, 2008 | none ahead |
| BeBetter Medits history only | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Biocadits history only | 10 open or running | phase 3since Dec 27, 2012 | Dec 27, 2012 | none ahead |
| CASI Pharmaceuticalsits history only | 10 open or running | phase 2since Nov 13, 2002 | Nov 13, 2002 | none ahead |
| Cytranits history only | 10 open or running | phase 2since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| Galvanize Therapeuticsits history only | 10 open or running | phase 4since Oct 13, 2022 | Oct 13, 2022 | none ahead |
| Gradalisits history only | 10 open or running | phase 2since May 29, 2013 | May 29, 2013 | none ahead |
| Hope Cancer Instituteits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Innovent Biologicsits history only | 10 open or running | phase 3since Oct 23, 2016 | Oct 23, 2016 | none ahead |
| Mabscaleits history only | 11 open or running | phase 3since Dec 8, 2022 | Dec 8, 2022 | Dec 2026phase 3 · NCT05654454 |
| Matrix Pharmaceuticalits history only | 10 open or running | phase 2since Aug 10, 2001 | Aug 10, 2001 | none ahead |
| NovoCureits history only | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| Optimum Therapeuticsits history only | 10 open or running | phase 2since Dec 22, 2009 | Dec 22, 2009 | none ahead |
| Pharmacosmosits history only | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| Shanghai Huaota Biopharmaceuticalits history only | 11 open or running | phase 3since Jan 13, 2026 | Jan 13, 2026 | Apr 10, 2028phase 3 · NCT07360132 |
| SOTIO a.s.its history only | 10 open or running | phase 2since Apr 4, 2014 | Apr 4, 2014 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Mar 15, 2012 | Mar 15, 2012 | none ahead |
| Theradexits history only | 10 open or running | phase 3since Oct 11, 2001 | Oct 11, 2001 | none ahead |
| UCBits history only | 10 open or running | phase 2since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| Windy Hill Medicalits history only | 10 open or running | phase 2since Apr 28, 2008 | Apr 28, 2008 | none ahead |
| Zydus Lifesciencesits history only | 10 open or running | phase 2since Jan 21, 2000 | Jan 21, 2000 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Daiichi Sankyo, AstraZeneca, Merck, Parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, Novotech (Australia) Pty, WuXi CDS Clinical Research (Shanghai), Valerio Therapeutics, Ortho Biotech, Tibotec Pharmaceutical and Medarex.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Apr 30, 2002.
- Dec 21, 2005Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00269152 · 122 enrolled · France, Germany, Spain
- May 10, 2006Phase 2 study in Breast NeoplasmsNCT00325234 · 135 enrolled · Germany, Italy, South Africa and more
- Jun 20, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00343291 · 121 enrolled · United States
- Jul 10, 20062 phase 2 studiesNCT00350792, NCT00356525
- Nov 17, 2006Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00402051 · 133 enrolled · Germany
- May 31, 2007Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00482014 · 120 enrolled · United States, India
- Jun 21, 20072 phase 2 studiesNCT00490711, NCT00494026
- Nov 24, 2009Phase 4 study in Carcinoma, Non-Small-Cell LungNCT01020786 · 109 enrolled · Japan
- Feb 3, 2010Phase 2 study in Head and Neck NeoplasmsNCT01063075 · 34 enrolled · United States, Canada
- Mar 3, 20102 phase 2 studies in Head and Neck NeoplasmsNCT01081041, NCT01087970
- Jul 8, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01160744 · 280 enrolled · United States, Belgium, Canada and more
- Sep 30, 2011Phase 1 study in GliomaNCT01445119 · 58 enrolled · United States
- Mar 16, 2015Phase 2 study in CarcinomaNCT02392507 · 54 enrolled · United States
- Oct 20, 2016Phase 2 study in Thoracic NeoplasmsNCT02941601 · United States, Belgium, Germany and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 30 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more | 2 | Withdrawn | Dec 2017 | 0 |
| NCT02392507Carcinoma · United States | 2 | Completed | Jan 29, 2018 | 54 |
| NCT01445119Glioma · United States | 1 | Completed | Jul 2013 | 58 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Jan 2014 | 280 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Aug 2013 | 69 |
| NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico | 2 | Completed | Aug 2013 | 187 |
| NCT01063075Head and Neck Neoplasms · United States, Canada | 2 | Completed | May 2015 | 34 |
| NCT01020786Carcinoma, Non-Small-Cell Lung · Japan | 4 | Completed | Mar 2011 | 109 |
| NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more | 2 | Terminated | Oct 2008 | 4 |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | 7 | |
| NCT00482014Carcinoma, Non-Small-Cell Lung · United States, India | 2 | Completed | Oct 2011 | 120 |
| NCT00402051Carcinoma, Non-Small-Cell Lung · Germany | 2 | Completed | Dec 2008 | 133 |
| NCT00356525Lung Neoplasms · United States, Brazil, India | 2 | Terminated | Jun 2008 | 41 |
| NCT00350792Carcinoma, Non-Small-Cell Lung · France | 2 | Completed | Nov 2008 | 62 |
| NCT00343291Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | May 2010 | 121 |
| NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more | 2 | Completed | Apr 2010 | 135 |
| NCT00269152Carcinoma, Non-Small-Cell Lung · France, Germany, Spain | 2 | Completed | Nov 2007 | 122 |
| NCT00191854Breast Neoplasms · Brazil, China, India and more | 2 | Completed | Aug 2008 | 147 |
| NCT00191451Breast Neoplasms · United States | 2 | Completed | Oct 2008 | 150 |
| NCT00191256Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 77 | |
| NCT00191230Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 70 | |
| NCT00190710Carcinoma, Non-Small-Cell Lung · United States | 3 | Completed | 242 | |
| NCT00097227Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2007 | 165 |
| NCT00097214Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2007 | 57 |
| NCT00072865Breast Neoplasms · Russian Federation | 2 | Completed | 50 | |
| NCT00063401Ovarian Neoplasms · United States | 2 | Completed | Jun 2006 | 39 |
| NCT00051506Lung Neoplasms · United States | 2 | Completed | ||
| NCT00051493Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | 50 | |
| NCT00042679Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | ||
| NCT00034541Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | May 2003 | 32 |
How it is read
Names in the registry
- “Carboplatin”, 110 entries
- “carboplatin”, 38 entries
- “Pemetrexed/Carboplatin”, 2 entries
- “CARBOPLATIN”, 2 entries
- “Carboplatin/Paclitaxel”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 72 studies
- Ovarian Neoplasms, 22 studies
- Breast Neoplasms, 17 studies
- Small Cell Lung Carcinoma, 10 studies
- Neoplasms, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.